{"id":"NCT05879107","sponsor":"GlaxoSmithKline","briefTitle":"Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults","officialTitle":"A Phase III, Open-label, Randomized, Controlled, Multi-Country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co Administered With PCV20 in Adults Aged 60\\xa0Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-05-26","primaryCompletion":"2023-12-06","completion":"2024-05-07","firstPosted":"2023-05-30","resultsPosted":"2025-05-18","lastUpdate":"2025-05-18"},"enrollment":1113,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"RSVPreF3 OA investigational vaccine","otherNames":["RSVPreF3 OA"]},{"type":"BIOLOGICAL","name":"PCV20","otherNames":["20 valent pneumococcal vaccine, Prevnar 20 (in US), Apexxnar (in Europe)"]}],"arms":[{"label":"Co-administration Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged â‰¥60 years of age.","primaryOutcome":{"measure":"Adjusted Geometric Mean Titers (GMT) of Opsonophagocytic (OP) Titers at 1 Month After the PCV20 Vaccination","timeFrame":"At Day 31","effectByArm":[{"arm":"Co-administration Group","deltaMin":74.7,"sd":null},{"arm":"Control Group","deltaMin":110.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":20},"locations":{"siteCount":38,"countries":["United States","Belgium","Poland","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":553},"commonTop":["Injection site pain","Fatigue","Myalgia","Headache","Arthralgia"]}}